Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 25, Issue 3, Pages 389-395Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2013.03.001
Keywords
-
Categories
Funding
- EU (ERC advanced PATHFINDER) [269019]
- Dutch Cancer Society [KUN2009-4402]
- Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM) [FES0908]
- NWO Spinoza award
Ask authors/readers for more resources
Cancer immunotherapy critically relies on the efficient presentation of tumor antigens to T-cells to elicit a potent antitumor immune response aimed at life-long protection against cancer recurrence. Recent advances in the nanovaccine field have now resulted in formulations that trigger strong anti-tumor responses. Nanovaccines are assemblies that are able to present tumor antigens and appropriate immune-stimulatory signals either directly to T-cells or indirectly via antigen-presenting dendritic cells. This review focuses on important aspects of nanovaccine design for dendritic cells, including the synergistic and cytosolic delivery of immunogenic compounds, as well as their passive and active targeting to dendritic cells. In addition, nanoparticles for direct T-cell activation are discussed, addressing features necessary to effectively mimic dendritic cell/T-cell interactions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available